Double-Action drug joins fight against tough esophageal cancer
NCT ID NCT06143748
Summary
This study is testing whether adding a new immunotherapy drug called cadonilimab to standard chemotherapy and radiation can better control locally advanced esophageal cancer that cannot be surgically removed. The trial will enroll 46 patients to see if this combination improves survival and reduces the chance of the cancer returning. Researchers will monitor how well patients respond and track any side effects of the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.